Analyst Ratings For Akebia Therapeutics Inc (NASDAQ:AKBA)
Today, Needham & Company LLC lowered its price target on Akebia Therapeutics Inc (NASDAQ:AKBA) to $18.00 per share.
There are 5 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Akebia Therapeutics Inc (NASDAQ:AKBA) is Buy with a consensus target price of $22.1667 per share, a potential 173.66% upside.
Some recent analyst ratings include
- 8/9/2018-Akebia Therapeutics Inc (NASDAQ:AKBA) had its Hold rating reiterated by Royal Bank of Canada with a $13.00 price target
- 6/29/2018-Akebia Therapeutics Inc (NASDAQ:AKBA) had its Buy rating reiterated by HC Wainwright
- 5/10/2018-Akebia Therapeutics Inc (NASDAQ:AKBA) had its Buy rating reiterated by Mizuho with a $24.00 price target
- 12/18/2017-Akebia Therapeutics Inc (NASDAQ:AKBA) has coverage initiated with a Overweight ➝ Overweight rating and $26.00 price target
- 12/7/2017-Akebia Therapeutics Inc (NASDAQ:AKBA) has coverage initiated with a Buy ➝ Buy rating and $30.00 price target
- 6/30/2017-Akebia Therapeutics Inc (NASDAQ:AKBA) had its Buy rating reiterated by Aegis
Recent Insider Trading Activity For Akebia Therapeutics Inc (NASDAQ:AKBA)
Akebia Therapeutics Inc (NASDAQ:AKBA) has insider ownership of 8.19% and institutional ownership of 75.99%.
- On 2/15/2018 Duane Nash, Director, sold 1,000 with an average share price of $14.62 per share and the total transaction amounting to $14,620.00.
- On 10/2/2017 Duane Nash, Director, sold 1,188 with an average share price of $19.64 per share and the total transaction amounting to $23,332.32.
- On 10/2/2017 Michel Dahan, SVP, sold 1,398 with an average share price of $19.64 per share and the total transaction amounting to $27,456.72.
- On 9/28/2017 Michel Dahan, SVP, sold 5,000 with an average share price of $19.30 per share and the total transaction amounting to $96,500.00.
- On 8/15/2017 Michel Dahan, SVP, sold 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
- On 7/5/2017 Muneer A Satter, Director, bought 1,034,482 with an average share price of $14.50 per share and the total transaction amounting to $14,999,989.00.
- On 7/3/2017 Duane Nash, Director, sold 990 with an average share price of $14.27 per share and the total transaction amounting to $14,127.30.
About Akebia Therapeutics Inc (NASDAQ:AKBA)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for Akebia Therapeutics Inc (NASDAQ:AKBA)
Shares of Akebia Therapeutics Inc closed the previous trading session at 8,09 −0,13 1,58 % with 8 shares trading hands.
